This fact sheet provides key takeaways and resources for lawmakers and was shared at the Capitol Hill briefing on September 14, 2018.
Key Takeaways:
- U.S.–Mexico agreement on 10 years keeps brand drug prices high for longer
- A renegotiated NAFTA should lower – not increase – drug prices for patients
- Higher drug prices abroad ≠ lower drug prices in the U.S.
- Imposes additional barrier to emerging biosimilars market in U.S.
- Growing export markets for generics and biosimilars is in U.S. national interest
Resources:
- North American Generic Drugmakers Call for Rejection of New Exclusivity Period for Biologics, August 28, 2018
- Trade Agreements Should Promote Patient Access to More Affordable Generics and Biosimilars, August 2018
- AAM and Sister Associations in Canada and Mexico: Governments Should Not Raise Drug Prices in Renegotiated NAFTA, September 29, 2017